FDA inspection
Padagis US LLC: FDA inspection ending May 13, 2004
FDA inspection 327141 · Voluntary Action Indicated (VAI) · Minneapolis, MN
Key facts
| Inspection ID | 327141 |
|---|---|
| Firm | Padagis US LLC |
| FEI number | 2127022 |
| Address | 3940 Quebec Ave N |
| City | Minneapolis |
| State | MN |
| ZIP | 55427-1244 |
| Fiscal year | 2004 |
| Inspection end date | May 13, 2004 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs|Generic Drug Evaluation|New Drug Evaluation|Post Mrkt Surv & Epid: Human Drugs |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- Yes Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data